You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Cognitive Impairment in Fall-Related Studies in Parkinson’s Disease

Abstract

Background: There is increasing evidence to suggest a tight relationship between cognitive impairment and falls in Parkinson’s disease (PD). Here, we draw attention to a potentially significant flaw in the existent falls-related research, namely the apparent exclusion of patients with cognitive impairment or dementia.

Objective: Our objective was to review all published, on-going or scheduled fall-related intervention studies, in order to investigate the extent to which cognitively impaired individuals with PD were included in these studies.

Methods: We analyzed published controlled trials regarding falls and PD in commonly used databases, as well as relevant ongoing clinical trials registered within the World Health Organization database, clinicaltrials.gov and the European Clinical Trials Database.

Results: Fourteen of the fifteen published studies included had explicit cognitive exclusion criteria as part of their study protocol. Most of the 54 on-going PD fall-related studies excluded patients with cognitive impairment.

Conclusions: This suggests that individuals with cognitive impairment or dementia are excluded from fall-related research studies. We strongly recommend that future work in this area should include a representative sample of patients with PD, including subjects with cognitive decline.

INTRODUCTION

Parkinson’s disease (PD) is a complex heterogeneous neurodegenerative disorder. In order to capture the overall picture of PD, it is important to consider not only the typical motor problems such as tremor, bradykinesia, postural instability, and levodopa-induced motor complications, but also non-motor symptoms, such as pain, depression and cognitive impairment. Mild cognitive impairment (MCI) and PD dementia (PDD) are frequent and incidence increases with age, disease duration, and disease severity [1]. Even though there is still some debate regarding the definition, MCI is considered a cognitive decline that is not normal for age but with basically normal functional activities, and that appears to place patients at risk of progressing to dementia[1–3].

A growing body of class II evidence suggests that there is an increased risk of falls in the presence of cognitive impairment [4–7] as well as in dementia [8, 9] and this trend is present in both community-dwelling and institutionalized older populations. An evidenced based review from the American Academy of Neurology (ANN) pooled data from five studies and indicated an absolute risk of falling of 47% among individuals with dementia during study follow-up [6, 10–13]. Similar findings were reported in populations with PD [14–17]. A randomized, placebo-controlled, crossover, double-blind study demonstrated that one acetylcholinesterase inhibitor, donepezil, may have some symptomatic effect on cognitive deficits with a concomitant significant reduction in the number of falls in non-demented individuals with PD [18].

A more restrictive protocol that reduces or eliminates cognitively impaired individuals from fall intervention studies may have a substantive impact on the representativeness of the study sample. Consequently, current findings with respect to pharmacological [18] and non-pharmacological interventions [19–22] may fall short in providing the best possible evidence for appropriate management in individuals with cognitive impairment and may not be able to be extrapolated to this population. This methodological flaw was recently also highlighted in the study by Amar (2015) that defended that individuals with PD with moderate cognitive impairment face complex problems and warrant inclusion in falls research [23]. Ultimately, if individuals with MCI or dementia are at greater risk for falls, they should be included in specific fall-related research studies in order for the results of these studies to be relevant and applicable to the types of patients seen in actual clinical practice.

The primary goal of this review was to assess the extent of inclusion of individuals with PD and with MCI or dementia in published, on-going or in planning clinical controlled trials which had falls and/or fall-related outcomes.

MATERIALS AND METHODS

Study design: Systematic review

Literature search for published studies

We conducted a systematic search for all controlled trials regarding pharmacologic and non-pharmacological interventions for falls in PD that were published as full text papers up to May 2015. We used the electronic databases Medline, EMBASE, Cochrane Library Central Database and PEDro using the MeSH terms “PD”, or “Parkinson disease” AND “falls” AND “intervention” AND “prevention” to complete the literature search. Full text copies of potentially relevant trials were retrieved and their reference lists were systematically checked.

Literature search for ongoing studies

We also analyzed the major characteristics of ongoing clinical trials from the online open-access World Health Organization (WHO-ICTRP), the Clinical trial.gov database and the European Clinical Trials database (EudraCT) that proposed to evaluate the efficacy and/or safety of therapeutic interventions for the prevention or management of falls in PD. Within these databases, a search was performed for ongoing controlled trials regarding PD and falls using the following keywords: “Parkinson diseaseANDfalls”. The studies were hand sorted to exclude duplicate entries and studies that were not related to therapeutic interventions for falls in PD. Data regarding study variables, particularly exclusion on the grounds of cognitive scores were extracted from each study.

Selection criteria for studies

We included published controlled trials regarding therapeutic interventions or prevention of falls for individuals with PD with fall or fall related outcomes. The type of participants in these interventions included: individuals with a diagnosis of PD; any duration and stage of PD; all ages; any drug, surgical or rehabilitation interventions; and any duration of intervention.

Data extraction

From the published and the on-going trials reviewed we searched the following information for source of support:

  • a) General characteristics of the trials (scientific study name or main identification number, year of publication, authors, publication status, study design, exclusion criteria related to cognition status, control group, gait and falls related inclusion criteria, drop-outs and adverse effects);

  • b) Characteristics of participants (number of participants in each group, age, gender, diagnostic criteria, disease severity measures);

  • c) Characteristics of interventions (type of intervention - pharmacological, surgical, physiotherapy/occupational/speech, dose, mode of administration, duration of follow up);

  • d) Characteristics of outcome measures (primary outcome measure, secondary or other outcomes and assessment method used for fall recording).

We determined the number of trials that excluded participants due to cognitive impairment regardless of the definition of cognitive impairment used. Extraction of all data was conducted by two independent reviewers (JMD and CG), with disagreements resolved by a third rater (JD).

RESULTS

Characteristics of included studies

Regarding the published intervention-related studies, the search in the databases identified 722 records, of which 15 trials met the inclusion criteria for this review, in which a total of 1380 individuals participated (Fig. 1). There were 14 trials evaluating a non-pharmacological intervention and 1 trial for pharmacological intervention. Thirteen of the trials [19, 20, 22, 24–32, 45] had a parallel group design and two cross-over trials [18, 21]. Chung et al. [18] was a randomized, placebo-controlled, crossover design and double-blind trial. All trials were published in a full paper format. The trial characteristics of the 15 controlled trials that met our pre-defined inclusion criteria are summarized in Table 1.

Regarding the ongoing clinical trials, as of May, 2015, there were 19 registered trials regarding falls in PD in the WHO-ICTRP that met the inclusion criteria. From the European Clinical Trials database 2 additional clinical pharmacological trials were included. Within the ClinicalTrials.gov database there were 33 registered trials regarding falls in PD after been when crossed check. The main characteristics of all on-going trials are described in Table 2.

Participant characteristics

Participant characteristics of published trials were variable (Table 1). A clear diagnosis of PD was predominant with the exception of one published trial [26] which instead included participants with a diagnosis of Parkinsonism and no delineation of the characteristics of that terminology. The majority of the studies included individuals in stage II-III on the Hoehn and Yahr scale although six studies also included individuals in stage I [26]. The mean age of participants across trials ranged from 63 (±8.0) and 74, 5 (±9.7) years. Fall history was a common inclusion criteria ranging from 2 or more falls in the previous 12 months to 2 or more near falls per week.

Participant characteristics of the on-going trials were also widely variable and are described in Table 2.

Exclusion criteria related to cognitive status

Fourteen of the fifteen published intervention-related studies (n = 14) had explicit cognition exclusion criteria included as part of the study protocol. One study did not mention cognition aspects in the exclusion or inclusion criteria [24]. Forty-two of the fifty-four of the on-going studies registered in the WHO, EudraCT and Clinical Trials.gov database also had explicit cognition exclusion criteria.

Exclusion based on cognitive scores indicative of dementia was common. Eleven published and thirty-one on-going studies included in this review excluded participants based on a low Mini Mental Status Examination (MMSE) score (with the cutoff scores ranging from “less than 23” to “25 or lower”) (N = 42). Harro (2014) excluded participants if they had impaired cognitive functioning evidenced by a score of 20 or less on the Saint Louis Mental Status Examination (SLUMS) [27]. None of the studies specifically considered mild cognitive impairment as part of the exclusion criteria.

Due to the consistent nature of the exclusion of individuals with MCI or dementia, we were unable to analyze possible variables or characteristics that could be related to the rate of exclusion by MCI or dementia.

Intervention characteristics

The interventions being investigated were widely varied and predominately studies of non-pharmacological (i.e. rehabilitation based) interventions with only one pharmacological intervention [18] of a total of 15 published intervention-related studies used in this review.

In the on-going studies, 41 were non-pharmacological while only 12 were pharmacologically based.

Physiotherapy was the primary component of the non-pharmacological interventions and included treadmill training alone or with turning exercises [15, 19, 27], cueing gait program [14, 27], strength and balance programs [12, 13, 16, 28, 29], home-based programs [16, 30], teaching strategies for falls preventions [13], tai chi and exercise programs [17], muscle power training [30, 45], technology-assisted balance and gait training [31], and hydrotherapy perturbation-based balance training [32].The duration of the interventions varied from minimum 6 weeks to 6 months. The only pharmacological intervention consisted of 6 weeks of donepezil or placebo with a 3 week washout between phases.

Common outcome measures used for falls assessment

Outcome measures related to falls included: rates of falling, frequency of falls, frequency of near falls, fear of falling, number of fallers, and number of injurious falls. This was repeatedly measured by using falls diaries, calendars, postcards, and telephone reminders or interviews.

Drop-outs and adverse effects

There were limited reporting regarding adherence, adverse events and drop-outs. The study by Nieuwboer et al. [21] reported that one participant dropped out 3 weeks after randomization due to a necessary change of drug. Ashburn et al. [20] reported that drop-outs occurred in the intervention group (1 partner unwell, 1 disliked exercises, 1 died, 1 withdrew for no reason, 1 withdrew due to falls) and control group (4 unwell, 2 died, and 1 moved away). Allen et al. [19] described that the exercise group had no major adverse events but had 3 drops outs, 1 due to no longer wished to participate and 2 developed health problems unrelated to the intervention. Chung et al. [18] reported that 4 participants dropped out before the second phase (2 on active drug, 1 each during placebo phase and washout) and were excluded from the data analysis. Additionally, before the second crossover period, 2 more participants withdrew but were included in the analysis. Goodwin et al. [24] reported one pelvic fracture by a control group participant.

DISCUSSION

There is a lack of inclusion of individuals with PD with mild cognitive impairment and/or dementia in fall-related intervention studies and this continues to be prevalent in currently ongoing and scheduled trials. This may represent a serious methodological flaw with implications regarding the interpretation and clinical application of current and future fall interventions. This ultimately may lead to – at least partly – inadequate treatment recommendations for those who “really” fall (i.e. the cognitively impaired patients), and may really be useful only for a minority of the target population.

Cognitive status factors have long been recognized as having an important impact on management in PD but are frequently not addressed in the context of physiotherapy. In particular, impaired attention and executive function may exacerbate the difficulties with multitasking and contribute to falls. Cognitively impaired individuals often lose the capacity to prioritize tasks and when performing a dual task activity, they tend to reduce priority and/or attention to the gait or balance task, and focus more upon the completion of the secondary task [33]. This places these individuals at an increased risk for falling under complex multitask circumstances testing [34]. In a study by Allcock et al. [35], it was shown that the association of attentional deficits with postural instability translates into increased fall frequency measured prospectively over a 1 year study period. Another 12-month longitudinal cohort study of 102 older people without dementia (52 subjects with PD and 50 age and sex-matched controls) concluded that mild cognitive impairment might contribute to falls risk beyond conventional risk factors in older people with and without PD [14].

These findings raise a fundamental question. Should individuals with MCI and/or dementia be more widely considered or even recruited for specific fall intervention studies? Cognitively impaired individuals may be less able to comply with certain treatment and assessment components of trials and may also have higher adverse events and drop-out rates. Additionally, the design of clinical trials typically attempts to minimize confounding variables. Certain forms of cognitive impairment may independently contribute to falls (e.g., impulsive movements related to frontal lobe dysfunction). Hence, excluding cognitive impairment is defensible on these bases and so doing interventions to reduce falls should initially be shown as efficacious among non-demented PD patients. Subsequently, the strategy could be applied to those with cognitive impairment. Burton et al., (2015) [36] recently did a systematic review and meta-analysis to evaluate the effectiveness of exercise programs to reduce falls in older people with dementia who are living in the community. Three RCTs [37–39], with high quality and one single-group pre- and post-test pilot study [40] were included. Participants were included if they had a diagnosis by a doctor/specialist, or a validated test, such as the Mini Mental State Examination (MMSE), Saint Louis Mental Status Examination (SLUMS), the Clinical Dementia Rating Scale, or the National Institute of Neurological and Communicative Disorders and Stroke, Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) Alzheimer’s criteria. Results from this review suggested that an exercise program may potentially assist in preventing falls of older people with dementia living in the community. If such inclusion is possible in people without PD but with dementia, it is plausible to think it can and should also be applied to PD patients with cognitive impairment.

A better understanding of the reasons that underlie the exclusion of individuals with cognitive impaired may allow clinicians and researchers to better identify possible solutions to overcome barriers associated to this exclusion. Due to the consistent nature of the exclusion of individuals with MCI or dementia in our review, we were unable to objectively analyze or identify any potential variables/characteristics (i.e. study type, number of participants, study duration, etc.) that could be related to the rate of exclusion by MCI or dementia. Additionally, the information provided by the WHO-ICTRP and in published trials was limited and insufficient to allow for a profound analysis of possible justifications for exclusion due to cognitive impairments. However, an important factor has to be noted. From our review, the reason for exclusion is dementia, as screened by tests of global cognitive dysfunction (i.e. Mini-Mental State Examination <24 and UPDRS part I). Different data collection methods for cognition are an important future line of research in this area because instruments such as the MMSE may not identify specific cognitive deficits, such as executive and attentional deficits which are the type of frontal lobe deficits that are more impaired in fallers [41]. Alternative options could include the Montreal Cognitive Assessment (MoCA), which is sensitive to frontal lobe dysfunction and has been shown to be effective as a bedside test for evaluating the risk of falls [42].

Future studies should attempt to design assessment and intervention procedures that include individuals with cognitive limitations by considering several strategies. Screening for cognitive deficits should routinely be included in the work-up of individuals with falls so clinicians can become aware of the testing with regards to the individuals profile and cross reference this data with physical capacity. Actively involving carers in monitoring and encouraging participation between therapist visits for the assigned exercise program was identified as a facilitating factor for inclusions of individuals with dementia [38, 39]. Participants and families may be more likely to enter a clinical trial if they properly understand the potential health benefits (e.g. improved quality of life) that could be realized via free high-quality treatment and follow-up by expert clinicians as part of the study. Difficulties associated with traveling to a facility may be minimized if performing the follow-up evaluations in the participant’s home is considered. Incorporating telemedicine and/or remote monitoring may also enhance the ability of this population to participate in many studies. Targeted cognitive training may offer a novel treatment option for falls that is worthy of an increased research and clinical focus. If the degree of cognitive impairment can affect the success of interventions for falls prevention [43]; cognitive training interventions may also be considered of particular interest to reduce this limitation as it may be able to improve cognitive processes thus reducing falls. Additionally, a study by Allan (2009) suggested that to prevent falls in mild-moderate dementia, possible management strategies could also include management of the potentially modifiable factors such as symptomatic orthostatic hypotension, autonomic symptoms and depression instead of prioritising strength and balance exercises that are more difficult for those with cognitive impairment to adhere [44]. Finally, appropriate resource support including financial support for such trials that recognizes the potential extra workload involved might better facilitate this recruitment. The existence of specific guidelines for recruiting cognitive impaired people may also increase the likelihood of researchers to recruit these individuals.

CONCLUSION

In conclusion, our findings suggests that due to the historical and ongoing exclusion of individuals with cognitive impairments, it is unclear if some intervention approaches for falls are effective and safe for this population. We highlight the substantial impact of restrictive protocol exclusion criteria on cognitive impaired PD patients. Even though participation of individuals with cognitive impairment in clinical trials may not always be desirable or feasible, it is still important to determine if they are disproportionately disqualified from participation and as a result, underrepresented in these trials, particularly in relationship to their respective motor problems.

Increasing participation of this population in clinical trials is critical in order to increase the external validity of the studies.

FINANCIAL DISCLOSURE/CONFLICT OF INTEREST RELATED TO RESEARCH COVERED IN THIS ARTICLE

All relevant disclosures and conflict of interests are detailed/ described/ listed at the end of this article.

Appendix

List of Ongoing Clinical trials identification name and registry number from the WHO, EudraCT and Clinical trial.gov databases.

WHO
1Boston University. A Multifactorial Exercise Program to Reduce Falls in People With Parkinson Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2014- [cited 2015 May 06]. Available from: http://clinicaltrials.gov/show/NCT02302144 NLM Identifier: NCT02302144.
2University of Nevada, Las Vegas. High-intensity Exercise and Fall Prevention Boot Camp for Parkinson’s Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2014- [cited 2015 May 06]. Available from: http://clinicaltrials.gov/show/NCT02230267 NLM Identifier: NCT02230267
3Canadian Institutes of Health Research, Alberta Innovates and Health Solutions and University of Calgary (Canada). Ambulosono - A music walking program for patients with Parkinson Disease. In: ISRCTNregistry [Internet]. BioMed Central 2014 - [cited 2015 May 06]. Available from: http://isrctn.com/ISRCTN06023392 NLM Identifier: ISRCTN06023392
4Southampton University Hospitals NHS Trust (UK). A randomised controlled trial of the effectiveness of PDSAFE to prevent falls among people with Parkinson disease. In: ISRCTNregistry [Internet]. BioMed Central 2014 - [cited 2015 May 06]. Available from: http://isrctn.com/ISRCTN48152791 NLM Identifier: ISRCTN48152791
5University of Southampton (UK). A randomised controlled trial of the effectiveness of PDSAFE to prevent falls among people with Parkinson disease: Stage 1 Pilot. In: ISRCTNregistry [Internet]. BioMed Central 2013- [cited 2015 May 06]. Available from: http://isrctn.com/ISRCTN14719805 NLM Identifier: ISRCTN14719805
6La Trobe University. A single group pilot study of the feasibility, safety and efficacy of an Argentine tango dance intervention for people living with Parkinson’s disease. In: ANZCTR.org.au [Internet]. Australian New Zealand Clinical Trials Registry 2013 -[cited 2015 May 06]. Available from: http://www.anzctr.org.au/ACTRN12613001058763.aspx
7VU University Medical Center (Netherlands). Improving Mobility and balance in Parkinson disease through circuit Class Training: Effects on clinical outcomes, posturography and brain connectivity. In: ISRCTNregistry [Internet]. BioMed Central 2013 - [cited 2015 May 06]. Available from: http://isrctn.com/ISRCTN47046299 NLM Identifier: ISRCTN47046299
8National Taiwan University Hospital. Freezing of Gait Correction and Fall Prevention in People With Parkinson’s Disease: Developing and Application of a Real-time Somatosensory Stimulation System. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2013- [cited 2015 May 06]. Available from: http://clinicaltrials.gov/show/NCT01772186 NLM Identifier: NCT01772186
9Tel-Aviv Sourasky Medical Center. V-TIME: A Treadmill Training Program Augmented by Virtual Reality to Decrease Fall Risk in Older Adults, Patients With Parkinson’s Disease and Individuals With Mild Cognitive Impairments. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2012- [cited 2015 May 06]. Available from: http://clinicaltrials.gov/show/NCT01732653 NLM Identifier: NCT01732653
10The Hong Kong Polytechnic University. Effects of an Innovative Balance Training Programme in Enhancing Postural Control and Reducing Falls in Patients With Parkinson’s Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2011- [cited 2015 May 06]. Available from: http://clinicaltrials.gov/show/NCT01427062 NLM Identifier: NCT01427062
11Department of Veterans Affairs. Effects of Vitamin D in Parkinson’s Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2010- [cited 2015 May 06]. Available from: http://clinicaltrials.gov/show/NCT01119131 NLM Identifier: NCT01119131
12Oregon Health and Science University. Cholinergic Augmentation in Frequently Falling Subjects With Parkinson’s Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2009- [cited 2015 May 06]. Available from: http://clinicaltrials.gov/show/NCT00912808 NLM Identifier: NCT00912808
13The University of Melbourne. Home based rehabilitation to reduce falls in people with Parkinson’s disease: a randomised controlled trial. In: ANZCTR.org.au [Internet]. Australian New Zealand Clinical Trials Registry 2008- [cited 2015 May 06]. Available from: http://www.anzctr.org.au/ACTRN12608000390381.aspx NLM Identifier: ACTRN12608000390381
14The University of Sydney. Exercise to prevent falls in people with Parkinson’s disease. In: ANZCTR.org.au [Internet]. Australian New Zealand Clinical Trials Registry 2008- [cited 2015 May 06]. Available from: http://www.anzctr.org.au/ACTRN12608000303347.aspx NLM Identifier: ACTRN12608000303347
15Radboud University. Reduction of Falls in the Elderly - Parkinson’s Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2007- [cited 2015 May 06]. Available from: http://clinicaltrials.gov/show/NCT00518648 NLM Identifier: NCT00518648
16Peninsula Medical School (UK). The effect of targeted exercise on falls and function for people with Parkinson’s disease (Group Exercise Trial for Parkinson’s disease - GET uP study). In: ISRCTNregistry [Internet]. BioMed Central 2007- [cited 2015 May 06]. Available from: http://isrctn.com/ISRCTN50793425 NLM Identifier: ISRCTN50793425
17Southampton University Hospitals NHS Trust (UK). Can support group-based exercise reduce risk factors for falling in people with Parkinson’s disease? In: ANZCTR.org.au [Internet]. Australian New Zealand Clinical Trials Registry 2007- [cited 2015 May 06]. Available from: http://www.anzctr.org.au/ACTRN12607000193471.aspx NLM Identifier: ACTRN12607000193471
18University of Melbourne. A randomized controlled trial of strategy training compared to exercises to prevent falls and improve mobility in people with Parkinson’s Disease. In: ANZCTR.org.au [Internet]. Australian New Zealand Clinical Trials Registry 2006- [cited 2015 May 06]. Available from: http://www.anzctr.org.au/ACTRN12606000344594.aspx NLM Identifier: ACTRN12606000344594
19Action Medical Research (UK). Randomised controlled trial of a home-based exercise programme to reduce fall frequency among people with Parkinson’s disease. In: ISRCTNregistry [Internet]. BioMed Central 2004- [cited 2015 May 06]. Available from: http://isrctn.com/ISRCTN63503875 NLM Identifier: ISRCTN63503875
EudraCT
1A randomised, double blind, placebo controlled trial to evaluate the effect of Rivastigmine on gait in people with Parkinson’s disease who have fallen. The ReSPonD Study. EudraCT Number: 2011-003053-25
2An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson’s Disease Subjects who Participated in the ADAGIO Study EudraCT Number: 2009-011541-24.
Clinical trial.gov
1Radboud University. Reduction of Falls in the Elderly - Parkinson’s Disease (REFINE-PD). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2007- [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT00518648. NLM Identifier: NCT00518648
2The Hong Kong Polytechnic University. The Effects of the Hopeful Outdoor Parkinson Exercise (HOPE) Program on Improving Balance Performance in Parkinsonian Non-fallers and Single Fallers. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2013 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT01799681. NLM Identifier: NCT01799681
3Radboud University. Efficiency of Physiotherapeutic Care in Parkinson’s Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2006 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT00330694. NLM Identifier: NCT00330694.
4Chelsea Therapeutics. A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson’s Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2010 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT01176240 NLM Identifier: NCT01176240
5Oregon Research Institute. Study of Tai Chi Exercise and Balance in Persons With Parkinson’s Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2008 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT00611481 NLM Identifier: NCT00611481.
6Department of Veterans Affairs. Telemedicine Intervention to Improve Physical Function. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2012 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT01639469. NLM Identifier: NCT01639469
7Katholieke Universiteit Leuven. Dual Task Practice in Parkinson’s Disease (Duality-PD). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2011 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT01375413. NLM Identifier: NCT01375413
8University of California, San Francisco. Computer-Based Balance Training for People With Parkinson’s Disease). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2010 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT01162226. NLM Identifier: NCT01162226
9Radboud University. Integrated Multidisciplinary Care for Parkinson’s Disease: a Controlled Trial. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2007 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT00518791. NLM Identifier: NCT00518791.
10Memorial Medical Center. The Effects of Vitamin D and Bone Loss in Parkinson’s Disease (PDVD3). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2009 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT00907972. NLM Identifier: NCT00907972
11Beth Israel Deaconess Medical Center. Laser Light Cues for Gait Freezing in Parkinson’s Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2006 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT00320242. NLM Identifier: NCT00320242
12Queen Elizabeth Hospital, Hong Kong. Effectiveness of Physiotherapy Interventions for Patients With Parkinson’s Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2010 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT01076712. NLM Identifier: NCT01076712
13McGill University Health Center. Tango for Treatment of Motor and Non-motor Manifestations in Parkinson’s Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2012 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT01573260. NLM Identifier: NCT01573260
14Chulalongkorn University. Treadmill and Music Cueing for Gait Training in Mild to Moderate Parkinson’s Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2008 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT00750945. NLM Identifier: NCT00750945
15University of British Columbia. Ambulosono Rasagiline Musical Walking Study. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2014 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT02207387. NLM Identifier: NCT02207387
16Laval University. The Effect of Exercise Training on Gait and Quality of Life in Parkinson’s Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2012 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT01701128. NLM Identifier: NCT01701128
17University of Erlangen-Nürnberg. Stability and Balance in Locomotion Through Exercise (StaBLE). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2013 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT01856244. NLM Identifier: NCT01856244
18New York Institute of Technology. Effect of Osteopathic Manipulative Medicine on Parkinson Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2014 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT02107638. NLM Identifier: NCT02107638
19Rush University Medical Center. Varenicline for Gait and Balance Impairment in Parkinson Disease (Chantix-PD). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2011 - [cited 2015 May 06]. Available from: http://www.svedem.sehttps://clinicaltrials.gov/ct2/show/NCT01341080. NLM Identifier: NCT01341080
20The Swedish Research Council. BETA Study: Improving Balance Function in Elderly by Progressive and Specific Training and Physical Activity. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2011 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT01417598.NLM Identifier: NCT01417598
21Oregon Health and Science University. Effects of Cholinergic Augmentation on Measures of Balance and Gait. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2014 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02206620. NLM Identifier: NCT02206620
22Oregon Health and Science University. The Effect of Donepezil on Gait and Balance in Parkinson’s Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2012 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT01521117. NLM Identifier: NCT01521117
23Stony Brook University. Walking While Talking: The Effect of Doing Two Things at Once in Individuals With Neurological Injury or Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2013 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT01917903. NLM Identifier: NCT01917903
24University of Sao Paulo. Spinal Cord Stimulation for the Treatment of Motor and Nonmotor Symptoms of Parkinson’s Disease (SCSPD). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT02388204. NLM Identifier: NCT02388204
25Henry Ford Health System. Study to Assess the Clinical Benefit and Safety of Droxidopa in Parkinson’s Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2014 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT02066571. NLM Identifier: NCT02066571
26Universidad de Granada. Exercise Intervention and Dexterity in Parkinson. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2012 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT01749917. NLM Identifier: NCT01749917
27University of Dublin, Trinity College. A Randomised Controlled Trial (RCT) to Evaluate Use of an Individual Auditory Cueing Device’s (IACD’s) on Freezing and Gait in People With Parkinson’s Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2008 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT0072746. NLM Identifier: NCT0072746.
28Habilita, Ospedale di Sarnico. Efficacy of a Robotic-assisted Gait Training in Addition to a Conventional Physical Therapy in Parkinson’s Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2014 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT02164162. NLM Identifier: NCT02164162
29University of Sao Paulo General Hospital. Balance Training in Parkinson’s Disease Using Cues. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2013 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT01960985. NLM Identifier: NCT01960985
30Boston University. Mobile Health Technology to Promote Physical Activity in Persons With Parkinson Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2013 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT01955889. NLM Identifier: NCT01955889
31University of Iceland. The Effect of High-Volume Walking With Visual Cues (VC) in Parkinson's Disease In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2011 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT01391741. NLM Identifier: NCT01391741
32Cliniques universitaires Saint-Luc- Université Catholique de Louvain. Effects of Exercise on Long-Range Autocorrelations in Parkinson’s Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT02419768. NLM Identifier: NCT02419768.
33Chelsea Therapeutics. A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2013 - [cited 2015 May 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT01927055. NLM Identifier: NCT01927055

CONFLICT OF INTERESTS

Bastiaan R. Bloem has served as an editorial board member of Movement Disorders, currently serves as an editorial board member of Physiotherapy Canada, is Associate Editor for the Journal of Parkinson’s disease, received honoraria from serving on the scientific advisory board for Danone, Glaxo-Smith-Kline, UCB and received research support from the Netherlands Organization for Scientific Research, the Michael J Fox Foundation, the Prinses Beatrix Foundation, the Stichting Parkinson Fonds, the National Parkinson Foundation and the Parkinson Vereniging.

Joaquim J. Ferreira has held consultancy functions with GlaxoSmithKline, Novartis, TEVA, Lundbeck, Solvay, Abbott, BIAL, Merck-Serono, Merz, Ipsen; has received grants from GlaxoSmithKline, Grunenthal, Fundaçao MSD (Portugal) and Teva; has been a member of the European Huntington Disease Network and has been employed by Centro Hospitalar Lisboa Norte, Faculdade de Medicina de Lisboa. None of the other authors have any financial disclosures to report.

REFERENCES

1 

Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B, Rodriguez-Oroz MC, Troster AI, Weintraub D2011MDS Task Force on mild cognitive impairment in Parkinson’s disease: Critical review of PD-MCIMov Disord2618141824

2 

Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, Brayne C, Kolachana BS, Weinberger DR, Sawcer SJ, Barker RA2009The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohortBrain13229582969

3 

Janvin CC, Larsen JP, Aarsland D, Hugdahl K2006Subtypes of mild cognitive impairment in Parkinson’s disease: Progression to dementiaMov Disord2113431349

4 

Asada T, Kariya T, Kinoshita T, Asaka A, Morikawa S, Yoshioka M, Kakuma T1996Predictors of fall-relatedinjuries among community-dwelling elderly people with dementiaAge Ageing252228

5 

Clark RD, Lord SR, Webster IW1993Clinical parameters associated with falls in an elderly populationGerontology39117123

6 

Lord SR, Clark RD1996Simple physiological and clinical tests for the accurate prediction of falling in older peopleGerontology42199203

7 

Salgado RI, Lord SR, Ehrlich F, Janji N, Rahman A2004Predictors of falling in elderly hospital patientsArch Gerontol Geriatr38213219

8 

Buchner DM, Larson EB1988Transfer bias and the association of cognitive impairment with fallsJ Gen Intern Med3254259

9 

Shaw FE2007Prevention of falls in older people with dementiaJ Neural Transm11412591264

10 

Morris JC, Rubin EH, Morris EJ, Mandel SA1987Senile dementia of the Alzheimer’s type: An important risk factor for serious fallsJ Gerontol42412417

11 

Nakamura T, Meguro K, Sasaki H1996Relationship between falls and stride length variability in seniledementia of the Alzheimer typeGerontology42108113

12 

Resnick B1999Falls in a community of older adults: Putting research into practiceClin Nurs Res8251266

13 

Tinetti ME, Speechley M, Ginter SF1988Risk factors for falls among elderly persons living in thecommunityN Engl J Med31917011707

14 

Camicioli R, Majumdar SR2010Relationship between mild cognitive impairment and falls in older people with and without Parkinson’s disease: 1-Year Prospective Cohort StudyGait Posture328791

15 

Latt MD, Lord SR, Morris JG, Fung VS2009Clinical and physiological assessments for elucidating falls risk in Parkinson’s diseaseMov Disord2412801289

16 

Melton LJ3rd, Leibson CL, Achenbach SJ, Bower JH, Maraganore DM, Oberg AL, Rocca WA2006Fracture risk after the diagnosis of Parkinson’s disease: Influence of concomitant dementiaMov Disord2113611367

17 

Wood BH, Bilclough JA, Bowron A, Walker RW2002Incidence and prediction of falls in Parkinson’s disease: Aprospective multidisciplinary studyJ Neurol Neurosurg Psychiatry72721725

18 

Chung KA, Lobb BM, Nutt JG, Horak FB2010Effects of a central cholinesterase inhibitor on reducing falls inParkinson diseaseNeurology7512631269

19 

Allen NE, Canning CG, Sherrington C, Lord SR, Latt MD, Close JCT, O’Rourke SD, Murray SM, Fung VSC2010The effects of an exercise program on fall risk factors in people with Parkinson’s disease: A randomized controlled trialMov Disord2512171225

20 

Ashburn A, Fazakarley L, Ballinger C, Pickering R, McLellan LD, Fitton C2007A randomised controlled trial of a home based exercise programme to reduce the risk of falling among people with Parkinson’s diseaseJ Neurol Neurosurg Psychiatry78678684

21 

Nieuwboer A, Kwakkel G, Rochester L, Jones D, van Wegen E, Willems AM, Chavret F, Hetherington V, Baker K, Lim I2007Cueing training in the home improves gait-related mobility in Parkinson’s disease: The RESCUE trialJ Neurol Neurosurg Psychiatry78134140

22 

Protas EJ, Mitchell K, Williams A, Qureshy H, Caroline K, Lai EC2005Gait and step training to reduce falls in Parkinson’s diseaseNeuroRehabilitation20183190

23 

Amar K, Stack E, Fitton C, Ashburn A, Roberts HC2015Fall frequency, predicting falls and participating in falls research: Similarities among people with Parkinson’s disease with and without cognitive impairmentParkinsonism Relat Disord215560

24 

Goodwin VA, Richards SH, Henley W, Ewings P, Taylor AH, Campbell JL2011An exercise intervention to prevent falls in people with Parkinson’s disease: A pragmatic randomised controlled trialJ Neurol Neurosurg Psychiatry8212321238

25 

Li F, Harmer P, Fitzgerald K, Eckstrom E, Stock R, Galver J, Maddalozzo G, Batya SS2012Tai chi and postural stability in patients with Parkinson’s diseaseN Engl J Med366511519

26 

Toole T, Maitland CG, Warren E, Hubmann MF, Panton L2005The effects of loading and unloading treadmillwalking on balance, gait, fall risk, and daily function in ParkinsonismNeuroRehabilitation20307322

27 

Harro CC, Shoemaker MJ, Frey O, Gamble AC, Harring KB, Karl KL, McDonald JD, Murray CJ, VanDyke JM, Tomassi EM, VanHaitsma RJ2014The effects of speed-dependent treadmill training and rhythmic auditory-cued overgroundwalking on balance function, fall incidence, and quality of life in individuals with idiopathic Parkinson’sdisease: A randomized controlled trialNeuroRehabilitation34541556

28 

Smania N, Corato E, Tinazzi M, Stanzani C, Fiaschi A, Girardi P, Gandolfi M2010Effect of balance training on postural instability in patients with idiopathic Parkinson’s diseaseNeurorehabil Neural Repair24826834

29 

Canning CG, Sherrington C, Lord SR, Close JC, Heritier S, Heller GZ, Howard K, Allen NE, Latt MD, Murray SM, O’Rourke SD, Paul SS, Song J, Fung VS2015Exercise for falls prevention in Parkinson disease: A randomized controlled trialNeurology84304312

30 

Paul SS, Canning CG, Song J, Fung VS, Sherrington C2014Leg muscle power is enhanced by training in people with Parkinson’s disease: A randomized controlled trialClin Rehabil28275288

31 

Shen X, Mak MK2015Technology-assisted balance and gait training reduces falls in patients with Parkinson’sdisease: A randomized controlled trial with 12-month follow-upNeurorehabil Neural Repair29103111

32 

Volpe D, Giantin MG, Maestri R, Frazzitta G2014Comparing the effects of hydrotherapy and land-based therapy on balance in patients with Parkinson’s disease: A randomized controlled pilot studyClin Rehabil2812101217

33 

Bloem BR, Valkenburg VV, Slabbekoorn M, Willemsen MD2001The Multiple Tasks Test: Development and normal strategiesGait Posture14191202

34 

Bloem BR, Valkenburg VV, Slabbekoorn M, van Dijk JG2001The multiple tasks testStrategies in Parkinson’s disease. Exp Brain Res137478486

35 

Allcock LM, Rowan EN, Steen IN, Wesnes K, Kenny RA, Burn DJ2009Impaired attention predicts falling in Parkinson’s diseaseParkinsonism Relat Disord15110115

36 

Burton E, Cavalheri V, Adams R, Browne CO, Bovery-Spencer P, Fenton AM, Campbell BW, Hill KD2015Effectiveness of exercise programs to reduce falls in older people with dementia living in the community: A systematic review and meta-analysisClin Interv Aging10421434

37 

Pitkala KH, Poysti MM, Laakkonen ML, Tilvis RS, Savikko N, Kautiainen H, Strandberg TE2013Effects of theFinnish Alzheimer disease exercise trial (FINALEX): A randomized controlled trialJAMA Intern Med173894901

38 

Suttanon P, Hill KD, Said CM, Williams SB, Byrne KN, LoGiudice D, Lautenschlager NT, Dodd KJ2013Feasibility, safety and preliminary evidence of the effectiveness of a home-based exercise programme for older people with Alzheimer’s disease: A pilot randomized controlled trialClin Rehabil27427438

39 

Wesson J, Clemson L, Brodaty H, Lord S, Taylor M, Gitlin L, Close J2013A feasibility study and pilot randomised trial of a tailored prevention program to reduce falls in older people with mild dementiaBMC Geriatric1389

40 

Mackintosh SF, Sheppard LA A Pilot. Falls-prevention Programme for Older People with Dementia from A Predominantly Italian Background. Hong Kong Physiotherapy Journal 23, 20-26.

41 

Hausdorff JM, Doniger GM, Springer S, Yogev G, Simon ES, Giladi N2006A common cognitive profile in elderly fallers and in patients with Parkinson’s disease: The prominence of impaired executive function and attentionExp Aging Res32411429

42 

Kim JS, Jang W, Cho JW, Ahn JY, Kim HT2013Bedside cognitive assessments and falls risk in Parkinson’s diseaseNeurol Sci347578

43 

Oliver D, Connelly JB, Victor CR, Shaw FE, Whitehead A, Genc Y, Vanoli A, Martin FC, Gosney MA2007Strategies to prevent falls and fractures in hospitals and care homes and effect of cognitive impairment: Systematic review and meta-analysesBM33482

44 

Allan LM, Ballard CG, Rowan EN, Kenny RA2009Incidence and Prediction of Falls in Dementia: A Prospective Study in Older PeoplePLoS One4e5521

45 

Morris ME, Menz HB, McGinley JL, Watts JJ, Huxham FE, Murphy AT, Danoudis ME, Iansek R2015A randomized controlled trial to reduce falls in people with Parkinson’s diseaseNeurorehabil Neural Repairdoi: 10.1177-1545968314565511

Figures and Tables

Fig.1

Flow diagram for data extraction.

Flow diagram for data extraction.
Table 1

Summary of characteristics of 15 published Clinical Trials regarding fall interventions in Parkinson disease

Study &study designParticipantsExclusion criteria related to cognitive statusGait and fall-related inclusion criteriaType of InterventionStudy DurationPrimary or Secondary outcomes related to fallsMethod of falls data collection
Toole, 2005 [26]23 participants with Parkinsonism.Significant dementia or other disorders of comprehension.Able to walk with firm, continuous support of onePhysiotherapy: Treadmill walking for 206 weeks with 4 weeks follow-up.PRIMARY OUTCOMES: Number of falls during dynamic posturography.Fall register during dynamic
RCT, Parallel.Stage 1–4 HY.person to help carry weight orminutes per day for 3 daysposturography.posturography
Age = 74.5±9.7 years.assist with balance.per week for 6 weeks.assessment.
Protas, 2005 [22]18 participants with idiopathic PD.Low scores on all scales of the Neurobehavioral Cognitive Status1) Postural instability and gait difficulty predominant PD, 2)Physiotherapy: gait and stepping and turning8 weeks with 2 week follow-up.PRIMARY OUTCOMES: Fall frequency.Phone call.
RCT, Parallel.Stage 3-4 HY.Examination (Cognistat).freezing episodes, and/or atraining on a treadmill.
Exercised grouphistory of falls, and 3) ability to1 hour per day, three times
age=71.3±7.4 years.stand and walk with or without assistance.per week for 8 weeks.
Control group age=73.7±8.5 years.
Nieuwboer,153 participantsCognitive impairmentMild to severe gaitPhysiotherapy:6 weeks with 6SECONDARY OUTCOMES:Falls diary to
2007 [21]with PD.(MMSE Scores <24)disturbance with score3-week home cueingweek follow-up.Falling as a measure of possibleindicate the
Single-blindStage 3-4 HY.superior to 1 on the Unifiedprogram using a prototypeadverse cueing effects.number of falls as a
randomisedExercise group age:Parkinson’s Disease Ratingcueing device, followed bymeasure of possible
crossover trial.72.7±9.6 years. Control group age: 71.6±8.8 years.Scale (UPDRS; item 29).3 weeks without training.program adverse effects.
Ashburn, 2007142 participantsFailure on screening test (MMSE).Patients with independentlyPhysiotherapy: muscle8 weeks with 6PRIMARY OUTCOMES:Monthly self-
[20]with PD,Non intact gross cognitivemobile, living at home in thestrengthening, range ofmonths follow-up.Self-reported falling or not at 8completed diaries.
RCT withStage 3-4 HY.impairment.community, experiencingmovement, balanceweeks and 6 months.
blindedExercise group ageFailure on screening test (MMSE).more than one fall in thetraining and walking (inside
assessment, Parallel.= 72,7±9.6 years. Control group=71.6±8.8 years.previous 12 months.and outside). Teaching of strategies for falls prevention and movement initiation and compensation.
Control group: usual care which included contact with a local PD nurse.
Allen, 2010 [19]48 participants with PD.Significant cognitive impairment (MMSE <24).1) Able to walk independently (with or without an aid);Physiotherapy: a monthly exercise class and6-months.SECONDARY OUTCOMES: Number of Falls. Falls risk factorsMonthly falls diaries.
RCT with blinded assessment, Parallel.Exercise group age= 66±10 years. Control Group age = 68±7 years.falling with a score of 25 cm2) fallen in the last year, or were deemed to be at risk of targeted leg muscle or less on the Functional Reach test or if they failed to reach criterion on one of the balance tests in the QuickScreen Clinical Falls Risk Assessments.exercised at home 3 times weekly. The intervention strength, balance, and freezing. Control group received usual care. Both groups received standardized falls prevention advice in the form of a booklet.(leg muscle weakness, poor balance, and freezing of gait).
Chung, 2010 [18]23 participants with probable idiopathicMMSE score <25 or nearly falling 2 or moreBaseline frequency of fallingPharmacological 6 weeks of donepezil or15 weeks.PRIMARY OUTCOMES: Number of daily falls and near falls.Weekly postcards.
Randomized, placebo-controlled, double-blind, double-blind, crossover.PD. Hoehn & Yahr staging indicating moderate baseline disease (mean 3.2, SD 0.4). Age 68.3±10.8 years.times per week.placebo with a 3-week washout between phases
Smania 2010 [28] RCT64 participants with idiopathic PD. Stage 3-4 HY. Experimental group age= 67.64±7.41. Control group age=67.26±7.18.MMSE score <23Outpatients that did not require assistance to rise from chairs or beds.Intervention group: balance training consisting of feedforward and feedback postural reactions training. Control group: active joint mobilization, muscle stretching, and motor coordination exercises.21 treatment sessions (50 minutes each) and a 1 month follow-up.PRIMARY OUTCOMES: Number of falls.Falls diary
Goodwin, 2011130 participantsCognitive status not mentioned asHistory of two or more falls inPhysiotherapy10 week groupPRIMARY OUTCOMES:Weekly diaries to
[24]with PD.exclusion criterior.the previous year and whoIntervention group: strengthinterventionNumber of falls.register Falls and
RCT, Parallel.Stage 1-4 HY.Excluded if unable to followwere able to mobilizeand balance trainingperiod and 10fall-related injuries.
Intervention groupwritten or verbal instructions inindependently.program withweek follow-up
age= 72.0±8.6 years. Control group age=70.1±8.3 years.English.supplementary home exercises. 10 once weekly group exercise sessions, with twice weekly home exercises. Control group: usual care with medical or allied health.period.
Li, 2012 [25]195 participantsMMSE score <24Ability to stand unaided and3 exercise intervention6 months with 3SECONDARY OUTCOMES:Monthly fall
RCT, Parallel.with PD. Stage 1-4 HY. Tai chi group age=68±9 years. Resistance Group age= 69±8 years.walk with or without an assistive device.groups: Tai Chi, resistance Training or stretching. 60-minute exercise sessions twice weekly for 24 weeks.months follow-up.Number of falls.calendars.
Harro, 201420 participants withSaint Louis Mental StatusAbility to walk continuouslySpeed-dependent treadmill6 weeks trainingSECONDARY OUTCOMES:Monthly self-report
[27]PD. Stage 1-3 HY.Examination (SLUMS) <20 or less.without physical assistance fortraining (SDTT) group.with 3 and 6Fall incidence.fall calendars
Single-blind RCTMean age 66.1 yrs.5 minutes with or without an assistive device.Rhythmic auditory-cued (RAC).month follow-up
Paul, 2014 [30]40 participants withMMSE score <24Ability to walk independentlyIntervention group: muscle12 weeks with 6SECONDARY OUTCOMES:Monthly falls diaries.
RCT, Parallel.PD.with or without an aid.power training.month follow-up.Number of falls in six months of
Stage 1-4 HY. Experimental group age= 68.1±5.6 Control group age=64.5±7.4 years.Control group: low intensity exercises of same muscle groups independently at home. 45 minutes, twice a week for 12 weeks.follow-up.
Volpe, 201434 participants withMMSE score <25Ability to walk without anyIntervention group:2 months.SECONDARY OUTCOMES:Falls diary or tele
[32]PD.assistance.hydrotherapy treatmentNumber of fallsphone interview.
RCT, Parallel.Stage 2.5-3 HY. Intervention Group age= 68±7. Control group age=66±8.with focus on perturbation-based balance training. Control group: land-based rehabilitation treatment with same type of exercises. 60 minutes of treatment, five days a week for two months.
Cannings,231 participantsMMSE score <24Ability to walk independentlyExercise group: PD-WEBB6 months.PRIMARY OUTCOMES:Monthly falls diaries.
2015 [29]with PD.with or without a walking aid,program with progressiveFall rates and proportion of
RCT, Parallel.Stage 2-4 HY.and one or more falls in thebalance and lower limbfallers during the intervention
Experimental grouppast year or at risk of fallsstrengthening exercises.period.
age= 71.4±8.1.based on physicalControl group: usual-care
Control group age=69.9±9.3.assessment.from their medical practitioner and community services. Exercises were practiced for 40 to 60 minutes, 3 times weekly for 6 months.
49 participants withMMSE score <23Ability to walk independentlyIntervention group:12-weekPRIMARY OUTCOMES:Monthly phone
Shen, 2015 [31]PD. Stage 2-3 HY. Experimental group age= 63.3±8.0. Control group age=65.3±8.5.for 10 meters.technology assisted balance and gait training. Active control group: strengthening exercises. 2 phases of 4-week Supervised laboratory training, 3 sessions per week, separated by 4 weeks of self-supervised home-based training at a frequency of 5 sessions per week.intervention period.number of fallers, fall rate, and the time to first fall.calls.
Morris, 2015 [45]210 participants with PD. Stage 1-4MMSE score <24Medically able and safe to performGroup 1: progressive resistance strength training14 months, with an initial 8 weeks ofPRIMARY OUTCOMES: falls rate.Monthly falls calendars.
RCT, Parallel.HY. All participants aged=67.9±9.6.the interventions.coupled with falls prevention education. Group 2: movement strategy training combined with falls prevention education, Control group: life-skills information not related to falls. 8 weeks of out-patient therapy once per week and a structured home program.intervention, followed by 12 months of ongoing falls measurement.

Abbreviations: MMSE = Mini-Mental State examination; RCT = Randomised controlled trial; HY = Hoehn & Yahr; PDQ39 = Parkinson’s Disease Questionnaire.

Table 2

Ongoing Clinical trials characteristics with individuals with Parkinson's disease regarding falls interventions from the WHO, EudraCT and Clinical trial.gov databases

SourceNumber of clinical studies
WHOEudraCTClinical trial.gov
Number of studies 19233
Study design
  Randomized control trial16227
  Controlled trial306
Exclusion by cognition status
  Excluded based on mini mental score12019
  Excluded based on other cognitive parameter416
  Missing data318
Type of Intervention
  Pharmacological228
  Surgical001
  Physiotherapy/occupational17024
Sample size
  Inferior 508019
  Between 50-100303
  Superior 1008211
Disease Stage
  Stage I-II014
  Stage II-III314
  Stage III-IV7014
  Stage V000
  Missing data9011
Method of falls data collecting
  Diaries607
  Calendars101
  Post cards000
  Phone calls102
  Questionnaires1107
  Missing data0216
Fall outcome measure
  Primary outcome815
  Secondary outcome4112
Study duration
  Inferior 8 weeks405
  Between 8-24 weeks4017
  Superior to 24 weeks829
  Missing data302
Recruiting Status
  Recruiting5012
  Non recruiting202
  Completed12013
  Other026